Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
The present disclosure relates to crystalline solids comprising a compound of Formula (I), wherein R is n-propyl, and methods of making compounds of Formula (I) wherein R is C1-C4 alkyl or C2-C4 alkenyl. The present disclosure also relates to crystalline solids comprising a compound of Formula (II), The present disclosure further relates to methods of preparing the crystalline solids, and pharmaceutical preparations of the crystalline solids, and use of such pharmaceutical preparations in treatment of diseases and conditions.
1. A crystalline solid comprising Compound 1:
having 2θ values 16.1, 20.1, and 24.5.
2. The crystalline solid of claim 1 , wherein the solid is anhydrous.
3. The crystalline solid of claim 1 , wherein said crystalline solid contains residual non-solvated solvent or residual non-hydrated water.
4. The crystalline solid of claim 1 , wherein said crystalline solid is non-hygroscopic.
5. A composition comprising the crystalline solid of claim 1 , wherein the composition comprises less than about 5% by weight propyl nicotinate.
6. A composition comprising the crystalline solid of claim 1 , wherein the composition comprises less than about 5% by weight Compound 2:
7. A composition comprising the crystalline solid of claim 1 , said composition comprising at least about 90% by weight of Compound 1.
8. A pharmaceutical composition comprising the crystalline solid of claim 1 , and further comprising one or more pharmaceutically acceptable excipients.
9. A method for preparing the crystalline solid of claim 1 , comprising:
a) dissolving Compound 1 in a solvent to form a solution; and
b) crystallizing Compound 1 from the solution to form the crystalline solid;
wherein the solvent is methanol or ethanol.
10. The method of claim 9 , wherein the solvent is methanol.
11. The method of claim 9 , wherein the solution is anhydrous.
12. The method of claim 9 , wherein the solvent is heated to a temperature during the dissolving step from about 30° C. to about 40° C.
13. The method of claim 9 , wherein crystallizing comprises forming a supersaturated solution from the solution, wherein the supersaturated solution is supersaturated with respect to Compound 1.
14. The method of claim 13 , wherein forming the supersaturated solution comprises adding an anti-solvent to the solution, lowering the temperature of the solution, reducing the volume of the solution, or any combination thereof.
15. The method of claim 9 , wherein crystallizing comprises adding a seed crystal to the solution, wherein the seed crystal comprises Compound 1.
16. A method of purifying Compound 1:
said method comprising:
a) dissolving Compound 1 in a solvent to form a solution; and
b) crystallizing the compound from the solution to form a solid of greater purity than the purity of Compound 1 dissolved in step (a), wherein said solid of greater purity is the crystalline solid of claim 1 ;
wherein the solvent is methanol or ethanol.
17. The method of claim 16 , where step (a) is performed with amorphous Compound 1, and wherein said solid of greater purity in step (b) has purity of greater than about 95% by weight.
18. A method of increasing NAD levels in a subject, the method comprising administering a crystalline solid according to claim 1 to the subject.
19. A method of treating or reducing the occurrence of a disease or disorder in a subject in need thereof, the method comprising administering a crystalline solid according to claim 1 to the subject.
20. A method of increasing NAD levels in a subject, the method comprising administering a composition according to claim 8 to the subject.
21. A method of treating or reducing the occurrence of a disease or disorder in a subject in need thereof, the method comprising administering a composition according to claim 8 to the subject.